Early diagnosis of cardiac involvement in systemic lupus erythematosus via global longitudinal strain (GLS) by speckle tracking echocardiography

Farahnaz Nikdoust¹, Elham Bolouri¹, Seyed Abdolhussein Tabatabaei*, Mahdi Goudarzvand², Seyyedeh Tahereh Faezi¹

¹Department of Cardiology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
²Department of Physiology and Pharmacology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
³Department of Rheumatology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Introduction

Systemic lupus erythematosus (SLE) myocarditis occurs in between 5% and 10% of patients with lupus. Global longitudinal strain (GLS) via speckle tracking echocardiography can detect cardiac involvement in patients suffering from SLE. We decided to determine the echocardiographic features and subsequent early diagnosis of cardiac involvement in patients with SLE utilizing the GLS index via speckle tracking echocardiography.

Methods: In this cross-sectional study, we compared female patients with SLE of at least 2 years’ duration and healthy controls in terms of the left ventricular (LV) GLS via speckle tracking echocardiography. After data collection in both groups, the GLS index and the ejection fraction were evaluated.

Results: We analyzed and compared the LV echocardiographic parameters of 33 patients with SLE (mean age=25.45±0.63 years) with those of 35 healthy controls (mean age=27±0.45 years). The apical 2-chamber view indicated a significant decrease in the LV GLS in the case group by comparison with the healthy controls (P=0.005). The LV GLS in the apical 3-chamber view was significantly lower in the case group than in the control group (P=0.006). The LV GLS in the apical 4-chamber view revealed no significant difference between the case and healthy control groups (P=0.2). While there was a significant difference between the case and control groups via the LV GLS (P=0.02), the LV ejection fraction measured with the Simpson method showed no significant difference between the 2 groups (P=0.96).

Conclusion: GLS speckle tracking echocardiography is a noninvasive method with diagnostic and prognostic values; it may, therefore, be a sensitive marker for the diagnosis of myocarditis and other cardiac involvements in patients with SLE.
myocardial dysfunction and prevent early mortality.\textsuperscript{21} We, accordingly, sought to evaluate subclinical cardiac disease with the aid of speckle tracking echocardiography in patients suffering from SLE.

**Materials and Methods**

This cross-sectional study recruited 33 female patients (age=20–30 years) with SLE of at least 2 years’ duration who referred to the Rheumatology Clinic of Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. Patients with a history of Libman–Sacks endocarditis, a left ventricular ejection fraction (LVEF) of less than 55%, and heart failure were excluded. Thirty-five age- and sex-matched healthy controls were selected from the hospital staff. Following admission, a detailed history was obtained from the patients and clinical examinations were performed by experienced physicians. Demographic variables—including age, sex, height, and weight—were recorded. The patients and controls were also checked for the presence of classic cardiovascular risk factors such as hypertension, diabetes mellitus, dyslipidemia, smoking, and a family history of premature coronary artery disease. Additionally, patients with a history of valvular heart disease, arrhythmias, and known coronary artery disease were excluded. The clinical parameters checked encompassed the heart rate, systolic and diastolic blood pressures, a history of myocardial infarction or stroke, and congestive cardiac failure.

After the collection of the baseline demographic and clinical data, all the participants were evaluated with transthoracic 2D color echocardiography and speckle tracking echocardiography by a single echocardiologist using a Philips Dimensions ultrasound system. The LV GLS was assessed in the apical 2-, 3-, and 4-chamber views. Echocardiographic parameters, including the diameter of the 4 chambers, were measured routinely. The LV systolic function and EF were measured using the Simpson method. The reference limits of all the echocardiographic parameters were defined according to the guidelines of the American Society of Echocardiography.\textsuperscript{8,10}

**Statistical analysis**

The normal distribution of the data in the 2 groups was assessed using the Kolmogorov–Smirnov test. The comparisons of the continuous variables between the 2 groups were analyzed with the SPSS software, version 18, using the Student t test or the Mann–Whitney U test. The results are expressed as means ± standard errors (SEs). A P value of less than 0.05 was considered the minimum significant difference of means.

**Results**

In this study, we analyzed and compared the LV echocardiographic parameters of 33 patients with SLE (mean age=25.45±0.63 years) with those of 35 healthy controls (mean age=27±0.45 years). The results of the apical 2-chamber view showed a significant decrease in the LV GLS in the case group in comparison with the healthy controls (P=0.005) (Figure 1). Similarly, in the comparison between the patients with SLE and the healthy controls in terms of the echocardiographic parameters, the LV GLS in the apical 3-chamber view was significantly lower in the case group than in the control group (P=0.006) (Figure 2). In contrast, the LV GLS in the apical 4-chamber view revealed no significant difference between the case and control groups (P=0.2) (Figure 3). Whereas the difference between the case and control groups as regards the LV GLS constituted a statistically significant difference (P=0.02) (Figure 4), the 2 study groups were not statistically significantly different concerning the LVEF measured with the Simpson method (P=0.96) (Figure 5).

**Discussion**

The availability of various treatment modalities has diminished the rate of death due to infections in patients with lupus. Nonetheless, death due to cardiac causes such as cardiomyopathy, arrhythmias, and heart failure plays a role as an independent factor in lupus.\textsuperscript{4} In an autopsy of patients with lupus, rates of cardiac involvement of between 40% and 50% have been reported, and between 7% and 10% of these cases of cardiac involvement are...
Global Longitudinal Strain in GLS

Figure 3. Apical 4-chamber view does not depict a significant difference in terms of a decreased LV GLS between the case group (n=33) and the healthy controls (n=35) (P=0.2).
The bars represent mean ± SE.
LV, Left ventricle; GLS, Global longitudinal strain; SLE, Systemic lupus erythematosus
**P<0.01 compared with the control group.

Figure 4. Measurement of the LV GLS shows a significant difference between the case group (n=33) and the control group (n=35) (P=0.02).
The bars represent mean ± SE.
LV, Left ventricle; GLS, Global longitudinal strain; SLE, Systemic lupus erythematosus
* P<0.05 compared with the control group.

Figure 5. LVEF (%) measured with the Simpson method in echocardiography shows no significant difference between the patients with SLE (n=33) and the healthy controls (n=35) (P=0.96). The data are presented as mean ± SE.
LVEF, Left ventricular ejection fraction; SLE, Systemic lupus erythematosus.

One of the new methods for assessing the LV function with 2D speckle tracking echocardiography is GLS measurement. GLS measurement is a relatively new, accurate, and non-operator method to evaluate the function of the heart by comparison with the traditional methods of determining the EF.

Studies have also shown that GLS measurement in comparison with the EF is a good predictor of mortality in patients with heart failure. In the onset of cardiovascular involvement in lupus, a significant change cannot be seen in the conventional EF measurement method. A measurement of the LV GLS may detect heart disease in lupus before the occurrence of a decreased EF.

In the present study, GLS and EF parameters in patients with SLE, but without cardiac symptoms, were compared with those of healthy subjects.

The results of the GLS assessment showed a significant decrease in the apical 2-, 3-, and global chamber views in the patients with SLE in comparison with the healthy subjects; nevertheless, no significant difference was found in the 4-chamber view results. Additionally, the LVEF finding in the patients with SLE indicated no significant decrease compared with the healthy controls.

In light of the above findings, it can be stated that an impairment in GLS can be used as an index for evaluating ventricular functions relative to the conventional EF measurement. In fact, GLS impairment has an early diagnostic and prognostic value. This finding is in line with the results of a study by Huang et al., who reported a reduction in the LV GLS in 2D echocardiography in their patients with lupus by comparison with their healthy subjects. A similar study, conducted in 2016 with the aid of speckle-tracking echocardiography to evaluate strain indices in patients suffering from lupus, indicated that the strain indices were decreased in the treatment-resistant lupus group compared with the non-resistant lupus group. These findings underscore the importance of strain in predicting the disease prognosis and response to treatment in patients with lupus.

A study in 2015 showed the predicting role of the GLS index in comparison with the EF index in chronic kidney disease. Cardiovascular disease is one of the causes of death in chronic kidney disease, which is mostly asymptomatic. Our research findings, in concordance with the findings of previous studies, indicate the predictive role of GLS in the LV function in patients with SLE. Several mechanisms have been suggested for cardiac involvement in patients with lupus. Indeed, chronic immune response, cytokine overactivity, and inflammatory progression contribute to cardiomyocyte apoptosis, ventricular dysfunction myocarditis, and finally heart failure. All these events increase the rate of cardiovascular mortality. Therefore, cardiovascular assessment in patients with lupus, even in non-symptomatic ones, appears to be crucial.

Given the limited research in this field in Iran, we conducted the current study in order to evaluate the early diagnosis of heart disease in patients with SLE by using the GLS index. We would, however, recommend further studies with the aid of GLS index.

Limitations

The major limitation of the current study is the relatively small number of its participants. SLE is not a common disease and it is difficult, as such, to find patients with SLE. Another drawback of note is the single-center design of this study in a university hospital. We would recommend a multicenter study including a large number of patients with SLE in the different stages of the disease.
Conclusion

Myocarditis and subsequent cardiac failure are a consequence of SLE. The GLS parameter in 2D speckle tracking echocardiography is a noninvasive cost-effective tool with a desirable diagnostic and prognostic value in patients with lupus myocarditis. GLS impairment was common in 2D speckle tracking echocardiography findings in our patients with lupus. Hence, it would be useful to consider screening 2D speckle tracking echocardiography in the routine care of patients with lupus to explore whether or not the GLS method would be cost-effective and beneficial for patients. Therefore, further investigations are needed on various aspects of cardiac involvement in lupus to determine the significance of GLS changes in autoimmune diseases such as lupus.

Ethical approval

All the participants signed a written informed consent before enrolment in the study, and the study protocol was approved by the Board of Research and Ethics Committee of Tehran University of Medical Sciences.

Competing interests

None.

References

1. Barutcu A, Aksu F, Ozcelik F, Barutcu CA, Umit GE, Pamuk ON, et al. Evaluation of early cardiac dysfunction in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Lupus 2015; 24(10):1019-28. doi: 10.1177/0961203315570164.

2. Tincani A, Rebaïoli CB, Taglietti M, Shoenfeld Y. Heart involvement in systemic lupus erythematosus, antiphospholipid syndrome and neonatal lupus. Rheumatology (Oxford) 2006;45 Suppl 4:i8-13. doi:10.1093/rheumatology/kei308

3. Miner JJ, Kim AH. Cardiac manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 2014;40(1):51-60. doi: 10.1016/j.rdc.2013.10.003.

4. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turrell M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus. 2005;14(9):683-6. doi:10.1191/0961203305lu2200oa

5. Smiti M, Salem TB, Larbi T, Sfaxi AB, Ghorbel IB, Lamloum M, et al. [Pericarditis in systemic lupus erythematosus: prevalence and clinical and immunologic characteristics]. Presse Med 2009;38(3):362-5.

6. Moysakis I, Tektonidou MG, Vasiliou VA, Samarkos M, Votellas V, Moustopoulos HM. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med 2007;120(7):636-42.

7. Guset G, Pop D, Pamfil C, Balaj R, Muresan L, Cismaru G, et al. Subclinical myocardial impairment in SLE: insights from novel ultrasound techniques and clinical determinants. Med Ultrason 2016;18(1):47-56. doi:10.11152/amu.2013.2066.181.zdr.

8. Teixeira AC, Bonfa E, Herskowitz N, Barbato AJ, Borba EE. Early detection of global and regional left ventricular diastolic dysfunction in systemic lupus erythematosus: the role of the echocardiography. Rev Bras Reumatol 2010;50(1):16-30.

9. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013;43(1):77-95. doi: 10.1016/j.semarthritis.2012.12.002.

10. Nikdoust F, Abedini M, Tabatabaei T. Cardiac involvement in systemic lupus erythematosus: echocardiographic evaluation. Iranian Heart Journal 2017; 18(2): 23-29.

11. Apte M, McGwin G, Vila LM, Kaslow RA, Alarcon GS, Reveille JD. Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort. Rheumatology 2007; 47: 362–367.

12. Wijetunga M, Rockson S. Myocarditis in systemic lupus erythematosus. Am J Med 2002; 113: 419–423.

13. Chow LH, Radio SJ, Sears TD, Mcmanus BM. Sensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol 1989;14(4):915-20.

14. Sagar S, Liu PP, Cooper LT. Myocarditis. Lancet 2012; 379: 738–747.

15. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 2009 8;53(17):1475-87. doi: 10.1016/j.jacc.2009.02.007.

16. Toit RD, Herbs PhG, Rensburg AV, Snyman HW, Reuter H, Doorbell AF. Speckle tracking echocardiography in acute lupus myocarditis: comparison to conventional echocardiography. Bioscience Ltd; 2017; 9-19.

17. Mosca L, Benjamin EJ, Berra K, Beazons JI, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American heart association. Circulation 2011; (11):1243-62.

18. Al-Mohaisen MA, Chan KL. Echocardiography in the Assessment of Patients with Rheumatologic Diseases. Curr Cardiol Rep 2016; 18 (8):72. doi: 10.1007/s11886-016-0757-2.

19. Elnady BM, Abdelghafar AS, Khalik ES, Algethami MM, Basisny AS, Al-Otaibi MD, et al. The implication of tissue Doppler echocardiography and cardiopulmonary exercise in early detection of cardiac dysfunction in systemic lupus erythematosus patients. Eur J Rheumatol 2016;3(3):109-117. doi:10.5152/eurjrheum.2016.16002.

20. Mavrogeni S, Koutsogeorgopoulou L, Dimitroulas T, Markoussis-Mavrogenis G, Kolovou G. Complementary role of cardiovascular imaging and laboratory indices in early detection of cardiovascular disease in systemic lupus erythematosus. Lupus 2017;26(3):227-236. doi: 10.1177/0961203316617810.

21. Prasad M, Hermann J, Gabriel SE, Weyand CM, Mulvagh S, Mankad R, et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol 2015 Mar;12(3):168-76. doi: 10.1038/nrcardio.2014.206.

22. Puntmann VO, D’Cruz D, Smith Z, Pastor A, Choong P, Voigt T, et al. Native myocardial t1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ Cardiovasc Imaging 2013;6(2):295-301. doi: 10.1161/CIRCIMAGING.112.000151.

23. Mavrogeni SI, Bratis K, Markoussis V, Spargias C, Papadopoulou E, Papametzopoulos S, et al. The
diagnostic role of cardiac magnetic resonance imaging in detecting myocardial inflammation in systemic lupus erythematosus. Differentiation from viral myocarditis. *Lupus* 2013;22: 34–43. doi: 10.1177/0961203312462265.

24. Belghitia H, Brette S, Laffite S, Reant P, Picard F, Serri K, et al. Automated function imaging: a new operator-independent strain method for assessing left ventricular function. *Arch Cardiovasc Dis* 2008;101(3):163-9.

25. Cho GY, Marwick TH, Kim HS, Kim MK, Hong KS, Oh DJ. Global 2-dimensional strain as a new prognosticator in patients with heart failure. *J Am Coll Cardiol* 2009; 54 (7):618–24.

26. Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. *Circ Cardiovasc Imaging* 2009; 2 (5): 356–64.

27. Huang BT, Yao HM, Huang H. Left ventricular remodeling and dysfunction in systemic lupus erythematosus: a three-dimensional speckle tracking study. *Echocardiography* 2014; 31 (9):1085–94.

28. Acar RD, Bulut M, Acar S, Eve SC, Fidan S, Yasin M, Izcı S, Gurbuz AS. Systemic lupus erythematosus disease activity index is related with increased aortic stiffness and decreased left ventricular strain as shown by two–dimensional speckle tracking echocardiography. *Turk Gogus Kelp Dana* 2016; 24 (1): 20–26.

29. Yamada S, Ishii H, Takahashi H, Aoyama T, Morita Y, Kasuga H, et al. Prognostic value of reduced left ventricular ejection fraction at start of hemodialysis therapy on cardiovascular and all-cause mortality in end-stage renal disease patients. *Clin J Am Soc Nephrol* 2010; 5 (10):1793–8.

30. Stallworthy EJ, Pilmore HL, Webster MW, Sidhu KK, Curry EM, Brown P, et al. Do Echocardiographic Parameters Predict Mortality in Patients With End-Stage Renal Disease? *Transplantation* 2013;27;95(10):1225–32. doi: 10.1097/TP.0b013e31828dbb50.

31. Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, et al. Tumor necrosis factor-α mediates cardiac remodeling and ventricular dysfunction after pressure overload state. *Circulation* 2007;115(11):1398–407.

32. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstock KL, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. *J Clin Invest* 1996;98(12):2854.

33. Pearson TA. Heightened risk of cardiovascular disease in patients with rheumatoid arthritis, heightened risk of cardiovascular disease in patients with rheumatoid arthritis. Introduction. *Am J Med* 2008;121(10 Suppl 1):S1-2. doi: 10.1016/j.amjmed.2008.06.009.